Adverse drug reaction corneal

Observational studies Topical bevacizumab (5 mg/ml five times a day for 0.5-12 months) was used in 27 patients (30 eyes) with corneal neovascularization due to several causes and not responding to conventional therapy [1 ]. In five patients (five eyes) new epithelial defects developed (which could have been due to the underlying disease). There were no drug-related ocular or systemic adverse events or allergic reactions. 

Observational studies The short-term and long-term safety of topical bevacizumab 5 mg/ml for progressive corneal neovascularization secondary to a variety of corneal diseases and not responding to conventional anti-inflammatory treatment have been evaluated in 30 eyes of 27 patients Five patients (five eyes) developed new corneal epithelial defects. The authors warned against using bevacizumab in patients with epithelial defects and neurotrophic keratopathy. There were no allergic reactions, ocular drug-related complaints, or systemic adverse reactions. 

---